This study aims to evaluate the short-term efficacy, pain reduction, quality of life (QQL) and toxicity of BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer. All cases were diagnosed and treated in Beijing Hospital from October 2009 to October 2014. A total sixty patients with advanced pancreatic cancer were divided into two groups. Thirty patients in the combination therapy group received chemotherapy combined with BSD2000 deep hyperthermia(twice per week). Another thirty patients in the chemotherapy therapy group were only given chemotherapy. Twenty-one days were one cycle. The short-term efficacy, pain relief, QQL and toxicity were evaluated after two cycles. All sixty patients were assessable for response. The response rates for the combination therapy group and the chemotherapy therapy group were 10% and 6.7%, respectively, while the disease control rates for the two groups were 83% and 76%, respectively. There was no significant different between the two groups (P>0.05). The combination group showed significant improvement in pain relief and QQL compared to the control group (P<0.05). There were some mild side effects, such as gas trointestinal toxicities and myelosuppression, but no significant difference between the two groups (P>0.05). There was no severe side effect in the two groups. Even though there was no difference in efficacy, the combination group did show pain reduction, improved QQL and tolerable toxicity. BSD2000 deep hyperthermia combined with chemotherapy in patients with advanced pancreatic cancer is worthily recommended in the clinical application.

advanced pancreatic cancer  /  hypertherapy  /  chemotherapy  /  pain and life-quality